L01DB03 • epirubicin • Antineoplastic and immunomodulating agents | Cytotoxic antibiotics and related substances | Anthracyclines and related substances
Epirubicin is a cytostatic medication used in the treatment of various types of cancer, such as breast cancer, bladder cancer, or sarcoma. It works by destroying cancer cells and stopping their multiplication. Administration is usually by intravenous infusion, under the strict supervision of a medical oncology team.
Treatment with epirubicin requires close monitoring, as it can affect healthy cells as well as cancer cells. It is important for patients to follow the treatment schedule and have regular tests to assess heart and blood function.
Side effects may include nausea, vomiting, hair loss, fatigue, decreased blood cell counts, or impaired heart function. In rare cases, severe allergic reactions or inflammation at the injection site may occur.
Epirubicin is an important medication in cancer treatment, but it requires constant medical supervision to manage side effects and ensure the effectiveness of therapy. Open communication with the doctor is essential throughout the treatment.
Substance: epirubicin
Date of last drug list: 01-04-2025
Commercial code: W52208001
Concentration: 50mg
Pharmaceutical form: powder for injection
Quantity: 1
Product type: generic
Prescription restrictions: S - Medicines prescription reserved for use in certain specialized fields.
Manufacturer: SINDAN-PHARMA S.R.L. - ROMANIA
Holder: TEVA B.V. - OLANDA
Number: 10049/2017/01
Shelf life: 4 years-after packing for marketing;after reconstitution-it is used immediately